PIK3CA and cancer: As HER3 has limited expression in immune cells (see above), we next asked whether the ability to reduce cancer-driving mTOR activity exclusively in HNSCC cells by anti-HER3 would enable us to elucidate the mechanisms by which aberrant PI3K/mTOR establishes an immune evasive tumor immune microenvironment (TIME).